Prevention and treatment of Clostridium difficile associated diarrhea by reconstitution of the microbiota

Human Vaccines & Immunotherapeutics
Noa Eliakim-Raz, Jihad Bishara

Abstract

This review summarizes the latest advances in treating and preventing Clostridium difficile infection (CDI), the most common infectious disease cause of nosocomial diarrhea in adults in developed countries. As customary antibiotic therapies against C. difficile, metronidazole and vancomycin, are broad spectrum, they affect greatly the gut microbiota, which result in very high recurrence rates. Therefore, new strategies are researched intensively. New therapies focus on limiting further destruction of the gut microbiota or restoring the microbiota to its pre-destructed state. These include new antibiotics, such as fidaxomicin, which demonstrates reduced CDI recurrences, among other new drugs, biotherapeutic strategies, mainly fecal microbiota transplantation but also competitive inhibition with non-toxigenic strains of C. difficile, and finally, monoclonal antibodies against C. difficile toxins which offer protection against recurrences.

References

Jun 30, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Fred A ZarMelinda B Davis
Jan 18, 2008·The Journal of Infectious Diseases·Ju Young ChangVincent B Young
Feb 4, 2011·The New England Journal of Medicine·Thomas J LouieUNKNOWN OPT-80-003 Clinical Study Group
Mar 19, 2011·Journal of Medical Microbiology·Ciarán P Kelly, Lorraine Kyne
Aug 17, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kathleen M MullaneSherwood L Gorbach
Feb 1, 2012·The American Journal of Gastroenterology·Matthew J HamiltonAlexander Khoruts
Jun 12, 2012·Vaccine·Ginamarie FogliaPatricia J Freda Pietrobon
Jan 18, 2013·The New England Journal of Medicine·Els van NoodJosbert J Keller
May 1, 2013·Microbiology·Robert G K DonaldAnnaliesa S Anderson
Feb 14, 2015·Infectious Disease Clinics of North America·Chandrabali Ghose, Ciarán P Kelly
Feb 26, 2015·The New England Journal of Medicine·Fernanda C LessaL Clifford McDonald
Dec 25, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Susy S HotaSusan M Poutanen
Jan 26, 2017·The New England Journal of Medicine·Mark H WilcoxUNKNOWN MODIFY I and MODIFY II Investigators
Dec 23, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Yafet MamoColleen S Kraft

❮ Previous
Next ❯

Citations

Aug 28, 2018·Human Vaccines & Immunotherapeutics·E C TampakiG Kouraklis
Jul 11, 2019·Human Vaccines & Immunotherapeutics·Dani Cohen, Khitam Muhsen

❮ Previous
Next ❯

Methods Mentioned

BETA
lavage

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacteriotherapy (ASM)

Bacteriotherapy, also known as fecal transplantation, involves the transfer of stool from a healthy donor into the gastrointestinal tract for the purpose of treating recurrent C. difficile colitis. Here is the latest on bacteriotherapy.

Bacteriotherapy

Bacteriotherapy, also known as fecal transplantation, involves the transfer of stool from a healthy donor into the gastrointestinal tract for the purpose of treating recurrent C. difficile colitis. Here is the latest on bacteriotherapy.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Nature Reviews. Gastroenterology & Hepatology
Larry K Kociolek, Dale N Gerding
The New England Journal of Medicine
Daniel A Leffler, J Thomas Lamont
The Medical Clinics of North America
Christopher L Knight, Christina Surawicz
Therapeutic Advances in Gastroenterology
Sahil Khanna, Darrell S Pardi
© 2022 Meta ULC. All rights reserved